Therapeutic Potential of Nucleic Acids when Combined with Extracellular Vesicles

Jurgielewicz, Brian J.; Stice, Steven L.; Yao, Yao

doi:10.14336/ad.2021.0708

Cited by 14 publications

(13 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extracellular vesicles (EVs) are lipid bilayer-containing particles released from cells, both in physiological and pathological conditions [ 20 ]. Stem cell-derived extracellular vesicles (SCEVs) retain the anti-aging characteristics [ 21 ] and avoid tumorigenesis and immune rejection of SCs [ 22 ].…”

Section: Scev-mirna In Vascular Agingmentioning

confidence: 99%

Stem Cell-derived Exosomal MicroRNA as Therapy for Vascular Age-related Diseases

Ren¹,

Guo²,

Liu³

et al. 2022

Aging and disease

View full text Add to dashboard Cite

Vascular age-related diseases describe a group of age-related chronic diseases that result in a considerable healthcare burden to society. Vascular aging includes structural changes and dysfunctions of endothelial cells (ECs) and smooth muscle cells (SMCs) in blood vessels. Compared with conventional treatment for vascular age-related diseases, stem cell (SC) therapy elicits better anti-aging effects via the inhibition/delay ECs and SMCs from entering senescence. Exosomal noncoding RNA (ncRNAs) in vascular aging and stem cell-derived exosomal microRNAs (SCEV-miRNAs), especially in mesenchymal stem cells, have an important role in the development of age-related diseases. This review summarizes SCEV-miRNAs of diverse origins that may play a vital role in treating subclinical and clinical stages of vascular age-related disorders. We further explored possible age-related pathways and molecular targets of SCEV-miRNA, which are associated with dysfunctions of ECs and SMCs in the senescent stage. Moreover, the perspectives and difficulties of SCEV-miRNA clinical translation are discussed. This review aims to provide greater understanding of the biology of vascular aging and to identify critical therapeutic targets for SCEV-miRNAs. Though still in its infancy, the potential value of SCEV-miRNAs for vascular age-related diseases is clear.

show abstract

Section: Scev-mirna In Vascular Agingmentioning

confidence: 99%

Stem Cell-derived Exosomal MicroRNA as Therapy for Vascular Age-related Diseases

Ren¹,

Guo²,

Liu³

et al. 2022

Aging and disease

View full text Add to dashboard Cite

show abstract

“…However, because liposomes are non-natural substances in the human body, problems such as immunogenicity and biotoxicity remain. On the other hand, EVs are natural substances with low immunogenicity and biotoxicity [103][104][105][106][107][108][109][110][111][112][113][114][115][116]. Cancer-cell-derived EVs include cancer antigens according to individual cancer types, and the anti-tumor immune response is induced by the uptake of dendritic cells, which are the main antigen-presenting cells [117][118][119][120].…”

Section: Micrornas In Ev-mediated Ddsmentioning

confidence: 99%

Extracellular Vesicles as Novel Drug-Delivery Systems through Intracellular Communications

Matsuzaka

Yashiro

2022

Membranes

View full text Add to dashboard Cite

Since it has been reported that extracellular vesicles (EVs) carry cargo using cell-to-cell comminication according to various in vivo situations, they are exprected to be applied as new drug-delivery systems (DDSs). In addition, non-coding RNAs, such as microRNAs (miRNAs), have attracted much attention as potential biomarkers in the encapsulated extracellular-vesicle (EV) form. EVs are bilayer-based lipids with heterogeneous populations of varying sizes and compositions. The EV-mediated transport of contents, which includes proteins, lipids, and nucleic acids, has attracted attention as a DDS through intracellular communication. Many reports have been made on the development of methods for introducing molecules into EVs and efficient methods for introducing them into target vesicles. In this review, we outline the possible molecular mechanisms by which miRNAs in exosomes participate in the post-transcriptional regulation of signaling pathways via cell–cell communication as novel DDSs, especially small EVs.

show abstract

“…Nucleic acid therapies have shown considerable promise in treating various neurological illnesses such as PD, and they provide numerous key benefits, including excellent target specificity, stability, minimal toxicity, and immunogenicity ( Jurgielewicz et al, 2021 ). The simplicity and predictability of chemical production of nucleic acid therapies, as well as the quick drug development mechanism and characteristic pharmacokinetic parallels, are all significant benefits ( Yamada, 2021 ).…”

Section: Therapeutic Potential Of These Approachesmentioning

confidence: 99%

Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies

Pandey

Singh²

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Parkinson’s disease is the second most common progressive neurodegenerative disease diagnosed mainly based on clinical symptoms caused by loss of nigrostriatal dopaminergic neurons. Although currently available pharmacological therapies provide symptomatic relief, however, the disease continues to progress eventually leading to severe motor and cognitive decline and reduced quality of life. The hallmark pathology of Parkinson’s disease includes intraneuronal inclusions known as Lewy bodies and Lewy neurites, including fibrillar α-synuclein aggregates. These aggregates can progressively spread across synaptically connected brain regions leading to emergence of disease symptoms with time. The α-synuclein level is considered important in its fibrillization and aggregation. Nucleic acid therapeutics have recently been shown to be effective in treating various neurological diseases, raising the possibility of developing innovative molecular therapies for Parkinson’s disease. In this review, we have described the advancements in genetic dysregulations in Parkinson’s disease along with the disease-modifying strategies involved in genetic regulation with particular focus on downregulation of α-synuclein gene using various novel technologies, notably antisense oligonucleotides, microRNA, short interfering RNA, short hairpin RNAs, DNA aptamers, and gene therapy of vector-assisted delivery system-based therapeutics. In addition, the current status of preclinical and clinical development for nucleic acid-based therapies for Parkinson’s disease have also been discussed along with their limitations and opportunities.

show abstract

Therapeutic Potential of Nucleic Acids when Combined with Extracellular Vesicles

Cited by 14 publications

References 152 publications

Stem Cell-derived Exosomal MicroRNA as Therapy for Vascular Age-related Diseases

Stem Cell-derived Exosomal MicroRNA as Therapy for Vascular Age-related Diseases

Extracellular Vesicles as Novel Drug-Delivery Systems through Intracellular Communications

Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies

Contact Info

Product

Resources

About